Ulcer Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Ulcer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 264 trials

Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1Phase 2

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

Ulcerative ColitisClostridium Difficile
Fondazione Policlinico Universitario Agostino Gemelli IRCCS64 enrolled1 locationNCT06071312
Recruiting
Phase 4

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Ulcerative Colitis
Takeda65 enrolled49 locationsNCT06095128
Recruiting
Phase 1Phase 2

Superdonor FMT in Patients With Ulcerative Colitis

Active Ulcerative Colitis
Fondazione Policlinico Universitario Agostino Gemelli IRCCS42 enrolled1 locationNCT05739864
Recruiting
Phase 4

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Crohn's DiseaseUlcerative Colitis
Takeda400 enrolled91 locationsNCT06581328
Recruiting

Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD

Ulcerative Colitis (UC)Crohns Disease
Asian Institute of Gastroenterology, India200 enrolled2 locationsNCT07431983
Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Indeterminate Colitis+1 more
University of North Carolina, Chapel Hill200 enrolled5 locationsNCT07237516
Recruiting
Not Applicable

Monitoring of Venous Ulcers Using a Bioimpedance Measurement Based Method and System

Venous Ulcer
CutoSense Oy20 enrolled2 locationsNCT05805137
Recruiting
Phase 3

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Ulcerative Colitis
AbbVie530 enrolled270 locationsNCT06880744
Recruiting

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

Ulcerative Colitis (UC)
Bristol-Myers Squibb150 enrolled17 locationsNCT07271069
Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag Ltd.220 enrolled1 locationNCT07242248
Recruiting
Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis
Takeda207 enrolled140 locationsNCT06254950
Recruiting
Phase 3

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Colitis UlcerativeArthritis, PsoriaticCrohns Disease+1 more
Janssen Research & Development, LLC196 enrolled30 locationsNCT06663332
Recruiting

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag G.m.b.H400 enrolled1 locationNCT07102368
Recruiting

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Crohn DiseaseColitis Ulcerative
Janssen Scientific Affairs, LLC1,056 enrolled1 locationNCT04372108
Recruiting

A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

Colitis Ulcerative
Xian-Janssen Pharmaceutical Ltd.200 enrolled1 locationNCT07302360
Recruiting
Phase 3

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche100 enrolled4 locationsNCT07158242
Recruiting

Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden

Ulcerative Colitis
Pfizer120 enrolled17 locationsNCT04338204
Recruiting
Phase 2

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

Crohn DiseaseUlcerative Colitis (UC)IBD
Assistance Publique - Hôpitaux de Paris45 enrolled1 locationNCT07300553
Recruiting
Phase 2

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Crohn's DiseaseUlcerative Colitis (UC)Inflammatory Bowel Disease (IBD)
Mirador Therapeutics, Inc.140 enrolled66 locationsNCT07113522